Employment Situation - The U.S. Bureau of Labor Statistics reported a job gain of +147K for June, exceeding the consensus estimate of +110K and the revised +144K for May [1][2] - The Unemployment Rate decreased to 4.1%, indicating a healthy labor market [1][2] Job Revisions - Revisions for the previous two months showed an increase, with May's job gain revised from +139K to +144K and April's from +147K to +158K, totaling an additional +16K jobs over the past two months [3] Sector Analysis - The Government sector contributed +73K jobs, while the Federal Government saw a loss of -7K jobs [4] - The Healthcare sector added +39K jobs, and Social Assistance added +19K jobs, while traditional sectors like Leisure & Hospitality and Trade/Transportation/Utilities were absent from the report [5] Interest Rate Implications - The strong jobs report may reduce the likelihood of the Federal Reserve cutting interest rates in the upcoming FOMC meeting, potentially delaying cuts until September [6] Jobless Claims - Initial Jobless Claims decreased to 233K from a revised 237K, which is below the expected 240K, indicating a moderation in the labor market narrative [7] - Continuing Claims remained stable at 1.964 million, suggesting that the labor market has not yet reached a critical threshold that would indicate weakness [8] Trade Balance - The U.S. Trade Deficit for May was reported at -$71.5 billion, an improvement from the March record low of -$138 billion, with April's deficit revised to -$60.3 billion [9] Market Expectations - Analysts anticipate a rebound in Factory Orders for May and mixed results for Services PMI, with both metrics expected to remain above the growth threshold of 50 [10][11]

General Principles - The company aims to strengthen management control over its subsidiaries and standardize internal operations to protect the rights of the company and its investors [1] - The company exercises shareholder rights through voting and appointing directors and supervisors to its subsidiaries, while also providing guidance and supervision [1][2] Management Principles - The management control over subsidiaries is intended to establish effective control mechanisms to enhance governance structure, asset management, and overall operational efficiency [1][2] - Subsidiaries must report significant business and financial matters that could impact the company [1][2] Establishment of Subsidiaries - The establishment of subsidiaries must comply with national laws and align with the company's strategic planning and core competitiveness [1][2] - Approval for establishing subsidiaries or mergers must follow the company's articles of association and investment management regulations [1][2] Governance Structure - The company collaborates with other shareholders to establish governance structures for subsidiaries, ensuring compliance with legal requirements [2] - The company appoints directors and supervisors to maintain governance oversight, with a majority of board members being company representatives [2][3] Financial Management - Subsidiaries must adhere to a unified accounting system and financial management practices dictated by the company [3] - Financial reports must be submitted timely, and the company has the right to audit and review subsidiary operations [3] Supervision and Accountability - The company supervises subsidiaries' operations, investments, and compliance with disclosure regulations [3] - Subsidiaries must maintain transparency and cannot engage in unauthorized financial activities [3] Miscellaneous Provisions - The provisions of this system will be executed in accordance with relevant laws and regulations, and the company board has the authority to interpret the system [4]

Core Points - The document outlines the management system for the shares held by directors and senior management of Anhui Huaren Health Pharmaceutical Co., Ltd, emphasizing the need for compliance with relevant laws and regulations [2][3][12] - It specifies the procedures for reporting share transactions by directors and senior management, including timelines for notification and disclosure [4][5][20] - The document establishes restrictions on the transfer of shares by directors and senior management, including limits on the number of shares that can be sold within a year and conditions under which shares cannot be transferred [6][8][19] Group 1 - The management system is established to enhance the oversight of shares held by directors and senior management, in accordance with the Company Law and Securities Law [2][3] - Directors and senior management must notify the board secretary in writing before buying or selling shares, and the board secretary is responsible for managing and verifying the information [4][12] - The document outlines the calculation of transferable shares, stating that newly acquired shares can only be transferred under specific conditions [3][5] Group 2 - Restrictions on share transfers include a maximum of 25% of total shares held per year and a six-month lock-up period after leaving the company [4][6][19] - Certain conditions prohibit directors and senior management from trading shares, such as during the period before financial report announcements and when under investigation for violations [8][18] - The document mandates that any changes in shareholding must be reported to the Shenzhen Stock Exchange within two trading days, including details of the transaction [20][9]

Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. is revising its Articles of Association to eliminate the supervisory board, transferring its responsibilities to the audit committee of the board of directors, in compliance with relevant laws and regulations [1][2][3]. Summary by Sections Reason for Revision - The revision is based on the requirements of the Company Law of the People's Republic of China and related regulations, which state that the supervisory board will no longer be established, and its functions will be assumed by the audit committee of the board of directors [1][2]. Details of the Revision - The specific changes to the Articles of Association include the removal of the supervisory board and the corresponding rules, with updates to terminology such as changing "shareholders' meeting" to "shareholders' assembly" and updating numerical representations [1][2][3]. Other Matters - The board of directors has requested the shareholders' meeting to authorize the management to handle subsequent registration changes and filing of the revised Articles of Association [2][3].

安徽华人健康医药股份有限公司 第一章 总则 第二章 信息披露暂缓与豁免的适用情形 第一条 为规范安徽华人健康医药股份有限公司（以下简称"公司"）信息披 露暂缓与豁免行为，确保公司依法合规履行信息披露义务，保护投资 者的合法权益，根据《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司信息披露暂缓与豁免管理规定》《深圳证券交 易所创业板股票上市规则》（以下简称"《上市规则》"）等相关法 律法规，并结合《公司章程》及公司《信息披露管理制度》等有关规 定，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露按照中国证券监督管理委员会（以下简称"中国 证监会"）及深圳证券交易所（以下简称"深交所"）规定或者要求披 露的内容，适用本制度。 第三条 公司应当审慎确定信息披露暂缓、豁免事项，并采取有效措施防止暂 缓或者豁免披露的信息泄露。 第四条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地披 露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者， 不得实施内幕交易、操纵市场等违法行为。 第十四条 公司和其他信息披露义务人应当在年度报告、半 ...

Core Points - The implementation details of the cumulative voting system aim to enhance the corporate governance structure of Anhui Huaren Health Pharmaceutical Co., Ltd. and protect the interests of minority shareholders [3] - The cumulative voting system allows shareholders to allocate their voting rights across multiple candidates when electing two or more directors, providing flexibility in voting [3][5] - The election process for directors must comply with the company's articles of association and relevant laws, ensuring a structured and transparent nomination and voting process [3][4] Section Summaries General Provisions - The cumulative voting system is established to improve corporate governance and protect minority shareholders' interests, in accordance with relevant laws and regulations [3] - The system allows shareholders to have voting rights equal to the number of shares they hold multiplied by the number of directors to be elected [3] Election and Voting of Directors - The board must inform shareholders about the cumulative voting method before the election, and appropriate ballots must be prepared [2][3] - The election of independent and non-independent directors is conducted separately, with specific voting rights allocated for each category [5] - Shareholders can concentrate or distribute their votes among candidates, but exceeding the allowed number of votes will render the ballot invalid [5] Nomination of Director Candidates - Candidates for the board must be nominated by shareholders holding at least 1% of the company's shares or by the board itself [3] - Nominators must obtain consent from candidates and ensure they meet the qualifications for directorship [3][4] Election Results and Procedures - The number of elected directors must meet the requirements set forth in the company's articles of association, with a majority of votes needed for election [4] - If the number of elected directors is insufficient, additional rounds of voting will be conducted until the required number is met [4]

Core Viewpoint - The document outlines the procedures and requirements for selecting and changing accounting firms for Anhui Huaren Health Pharmaceutical Co., Ltd, emphasizing the importance of maintaining independence and quality in the auditing process [1][2][3]. Group 1: General Principles - The audit fees for the accounting firm are determined by the shareholders' meeting [1] - The controlling shareholders and actual controllers are prohibited from designating accounting firms or interfering with the audit committee's independent duties [1] - The selection of accounting firms must comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][2] Group 2: Requirements for Accounting Firms - Selected accounting firms must possess independent qualifications and meet the requirements set by the China Securities Regulatory Commission [1][2] - Firms must have a fixed workplace, sound organizational structure, and robust internal management systems [1] - The auditing team must include registered accountants who have not faced criminal or administrative penalties related to their professional conduct in the last three years [1][2] Group 3: Selection Procedures - The audit committee, independent directors, or a majority of the board can propose the hiring of an accounting firm [2][3] - The selection process must be competitive, utilizing methods such as competitive negotiation, public bidding, or invitation to tender [2][3] - The company must publicly disclose the selection documents, including evaluation criteria and scoring standards [2][3] Group 4: Evaluation and Reporting - The audit committee is responsible for evaluating the performance of the accounting firm annually and reporting to the board [2][3] - Evaluation criteria must include audit fees, qualifications, quality management, and risk management capabilities [4][5] - Significant changes in audit fees (over 20%) must be disclosed, including reasons for the change [6] Group 5: Change of Accounting Firms - The company must change accounting firms under specific circumstances, such as quality issues or failure to meet obligations [8][9] - The audit committee must communicate with both the outgoing and incoming firms to assess quality and integrity [9][10] - The reasons for changing firms must be disclosed, along with communication details with the previous firm [11][12]

安徽华人健康医药股份有限公司 第一条 为加强安徽华人健康医药股份有限公司（以下简称"公司"）市值管理 工作，进一步规范公司的市值管理行为，维护公司、投资者及其他利益 相关者的合法权益，依据《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司监管指引第 10 号——市值管理》《深圳证券交易所 创业板股票上市规则》等其他有关法律法规，结合公司实际情况，制订 本制度。 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升公司投 资价值和股东回报能力而实施的战略管理行为。 （一） 合规性原则：公司市值管理行为必须建立在法律法规及监管规则 的基础上实施。 （二） 系统性原则：鉴于公司市值受到多种因素影响，市值管理策略需 遵循系统思考与整体推进的核心理念，全面改善并优化推动市值 增长的关键要素组合。 （三） 科学性原则：市值管理应遵循其固有的客观规律，采取科学严谨 的方法进行市值管理行动，公司须通过科学的市值管理行为，确 保市值管理的科学与高效。 （四） 常态化原则：鉴于公司市值成长是一个长期且动态演变的过程， 市值管理应作为一项持续、常态化的战略任务，不断适应市场变 化，促进市场价值体现。 （五） ...

Core Points - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., was established to protect the rights and interests of shareholders, employees, and creditors, and to regulate its organization and behavior according to relevant laws [3][4] - The company was registered with a capital of RMB 400.01 million and is a permanent corporation [4][5] - The company issued 60.01 million shares to the public and was listed on the Shenzhen Stock Exchange on March 1, 2023 [3][4] Chapter Summaries General Provisions - The company is established in accordance with the Company Law and other relevant regulations [3] - The legal representative of the company is the chairman, who is responsible for civil activities conducted in the company's name [4][5] - The company operates under the principle of "quality first, integrity-based" [4][5] Business Objectives and Scope - The registered name of the company is Anhui Huaren Health Pharmaceutical Co., Ltd., with its address in Hefei City [4] - The business scope includes drug wholesale, food sales, medical device sales, and various consulting services [4][5] Shares - The company has issued a total of 40.01 million shares, all of which are ordinary shares [6] - The company can provide financial assistance for others to acquire its shares, with a limit of 10% of the total issued capital [6][7] Shareholder and Shareholder Meeting - Shareholders have rights to dividends, attend meetings, and supervise the company's operations [16][19] - The company must hold an annual general meeting within six months after the end of the previous fiscal year [26][27] - Shareholders holding more than 10% of shares can request a temporary meeting [29][30] Voting and Resolutions - Resolutions can be ordinary or special, requiring a majority or two-thirds majority of the voting rights, respectively [79] - The company must ensure that the meeting records are accurate and preserved for at least ten years [41]

安徽华人健康医药股份有限公司 内幕信息知情人登记管理制度 第一章 总则 董事会秘书具体负责公司内幕信息的日常管理工作，证券部是公司信息 披露管理、投资者关系管理、内幕信息登记备案的日常办事机构。 公司审计委员会对内幕信息知情人登记管理制度实施情况进行监督。 第二章 内幕信息及内幕信息知情人的范围 第六条 本制度所指内幕信息是指根据《证券法》相关规定，涉及公司的经营、 财务或者对公司股票、证券及其衍生品种交易价格有重大影响的尚未公 开的信息。包括但不限于： （一）公司的经营方针和经营范围的重大变化； （二）公司的重大投资行为，公司在一年内购买、出售重大资产超过公 司资产总额百分之三十，或者公司营业用主要资产的抵押、质押、出售 或者报废一次超过该资产的百分之三十； （三）公司订立重要合同、提供重大担保或者从事关联交易，可能对公 司的资产、负债、权益和经营成果产生重要影响； （四）公司发生重大债务和未能清偿到期债务的违约情况； （五）公司发生重大亏损或者重大损失； （六）公司生产经营的外部条件发生的重大变化； （七）公司的董事、或者总裁发生变动，董事长或者总裁无法履行职责； （八）持有公司百分之五以上股份的股东或者 ...